Clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases.
We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG)
Primary Therapeutic Areas
1.0 Therapeutic & Diagnostic
1.10 Small Molecules